The effects of DLL3 in axial skeletal development and glioma by D'Amico, Rachel
The effects of DLL3 in axial skeletal 
development and glioma  
 
 
A Senior Honors Thesis  
Presented in partial fulfillment of the requirements for Graduation with 
Research Distinction in the School of Health and Rehabilitation Sciences 
at The Ohio State University 
 
 
 
Rachel D’Amico 
April 7, 2014 
 
Advisor: Susan E. Cole, PhD, Department of Molecular Genetics 
 
 2 
Table of Contents 
1. Abstract.....................................................................................        3 
2. Table of Figures........................................................................        4 
 
3. Introduction..............................................................................         5 
4. Objectives.................................................................................       17 
5. Materials and Methods.............................................................       18 
6. Results Pertaining to Segmentation.........................................        22 
7. Results Pertaining to Glioma...................................................        27 
8. Discussion................................................................................       33 
9. Acknowledgments..................................................................       39 
10. References..............................................................................       40 
 
 
 
 
 
 
 
 3 
Abstract 
The Notch pathway is critical for normal development of the skeleton and nervous system. 
Dysregulation of Notch can also promote glioma, cancer of the glial cells. Tight regulation of 
Notch is achieved by modulating pathway activity through inhibitory ligands (like DLL3) and/or 
glycosyltransferases that affect receptor-ligand interactions (like Lunatic Fringe). In most 
contexts, increased Lfng causes an increase in Notch activity, while Dll3 expression causes a 
decrease in Notch activity. Our project looked at this modulation in two systems: axial skeletal 
development and glioma cells. In the presomitic mesoderm (PSM), loss of Lfng increases Notch 
activity while a loss of Dll3 causes a decrease in Notch activity. Examination of skeletal 
phenotypes and Notch activation patterns in double knockout mice shows that the Dll3-null 
phenotype is epistatic to the Lfng-null phenotype in the posterior PSM, suggesting that in a 
molecular clock-dependent setting, LFNG acts through DLL3 to inhibit Notch activation. 
However, in the anterior PSM, LFNG and DLL3 work through different pathways to regulate 
Notch. In contrast, in glioma Notch signaling maintains glioma stem cells, which worsen 
outcomes. Increased Dll3 expression in glioma tumors leads to better prognosis, suggesting 
DLL3 may inhibit Notch activity. To study this hypothesis, we used Luciferase assays in glioma 
cells stably transfected with a luciferase gene under the control of a Notch-dependent promoter, 
as well as MTS viability assays. We found that increasing Dll3 expression decreases Notch 
signaling, but does not affect cell viability (a Notch-independent phenotype). DLL3 appears to 
be a promising inhibitor of Notch activity in glioma cells, suggesting it could be targeted in 
future treatment options. We have found that regulation of Notch is highly context dependent, 
both in development and disease. 
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Introduction 
I. The Notch pathway 
 The Notch signaling pathway is highly conserved in vertebrates, and is essential to 
controlling cell fate through differentiation. In some cases, it helps to maintain stem cell 
populations, and once the cells are ready to differentiate, promotes one cell type over another, 
thus ensuring not all cells commit to the same fate (Bray, 2006). When mutated, dysregulated 
Notch signaling is known to have pathogenic effects. Mutations in members of the Notch 
pathway lead to Alagille syndrome, spondylocostal dysostosis, and cerebral arteriopathy 
(reviewed in Gridley, 2003). Further, dysregulated Notch activity has been detected in many 
different cancers (Koch and Radtke, 2007). 
A. Notch has a complex mechanism of action 
Notch activity is controlled by its interactions with DSL (Delta, Serrate, Lag2) ligands. The 
Notch receptor is synthesized as a polypeptide, then displayed as a transmembrane protein, with 
multiple epidermal growth factor (EGF)-like repeats available for ligand binding. When 
interaction occurs with a DSL ligand on a neighboring cell, the extracellular domain of Notch is 
cleaved by ADAM, a metalloprotease. The Notch intracellular domain (NICD) is then cleaved 
from the membrane-spanning region by γ-secretase (encoded by Presenilins 1 and 2) on the 
inside of the cell membrane. NICD translocates to the nucleus, where it binds to the transcription 
factor CBF-1. CBF-1 then turns the CSL complex from a transcription repressor to an activator, 
and CSL activates Notch’s target genes, like the Hes family, which regulate transcription and 
prevent neural differentiation gene expression (as reviewed by D’Souza, 2010). 
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Figure 1. Notch receptors undergo trans-activation/cis-inactivation with DSL ligands. When a 
Notch receptor and a ligand are expressed on neighboring cells, the proteins bind together. ADAM 
metalloprotease releases the extracellular portion of the receptor while gamma-secretase cleaves 
Notch intracellularly. This produces the Notch Intracellular Domain, or NICD, which translocates 
to the nucleus and controls transcription of its target genes. If the Notch receptor is expressed in 
the same cell as the ligand, the ligand inhibits binding to an extracellular ligand, and thus prevents 
the release of the NICD fragment and activation of the pathway. 
 
A unique feature of the Notch pathway is ligand trans-activation/cis-inactivation. If Notch is 
expressed in a cell next to a ligand-expressing cell, then the ligand is able to initiate cleavage of 
Notch and activation of its pathway. But when a ligand is expressed in the same cell as Notch, 
NICD release and action can be inhibited (Bray, 2006). This most likely evolved as a way to 
provide regulation of the pathway, preventing all cells from entering the same cell fate, and to 
direct tissue patterning in a polarizing way. No two neighboring cells will both express activated 
Notch, ensuring ample tissue variation. 
B. Notch signaling is upregulated in many cancers 
The Notch pathway has been shown to be overexpressed in leukemia, medulloblastoma, 
melanoma, breast, pancreatic, and colorectal cancers. Two thirds of ductal carcinoma tumors 
were found to be positive for Notch-1 staining and half of all breast cancer tumors had loss of 
Numb expression, a negative regulator of the Notch pathway, indicating Notch’s widespread 
effects and importance in cancer. Interestingly, while in most cases it is oncogenic, Notch-1 is 
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capable of also acting as a tumor suppressor. Animals with downregulated Notch-1 expression in 
skin cells develop basal cell tumors (most likely due to its role in Shh and Wnt signaling), and 
Notch-1 deficient skin is more susceptible to cancer. The Notch pathway is also important as a 
tumor suppressor in hepatocellular, skin, and small cell lung cancers (reviewed in Koch and 
Radtke, 2007). These contrasting roles are reminiscent of Notch’s ability to either promote 
progenitor stages or induce differentiation depending on the tissue. 
Notch signaling was first shown to be of importance in glioma in 2002, when it was found 
that human glioma cells preferentially overexpress Jagged1 and DLL1, both Notch ligands 
(Ignatova et al., 2002). Inactive Notch signaling is one of the defining characteristics of low-
grade glioma, and has been experimentally shown to be significant in outcome. When Notch-1 
activity is repressed, it causes decreased proliferation, increased apoptosis, and decreased 
tumorigenic capabilities (Purow et al., 2005). Conversely, overexpressing Notch-1 in glioma 
cells increases their growth rates and colony formation, as well as stem cell expression markers 
like Nestin (Zhang et al., 2008).  
Recently, a phase I study tested the γ-secretase inhibitor (which prevents the release of the 
activated NICD fragment) MK-0752 in patients with solid tumors. The most significant response 
was observed in patients with central nervous system cancers. Ten out of the twelve patients that 
exhibited prolonged stable disease had glioma, and one patient with anaplastic (grade III) 
astrocytoma exhibited a complete response for over a year (Krop et al., 2012). This demonstrates 
the drug’s ability to cross the blood-brain barrier and navigate the extracellular matrix, both of 
which are of major concern in glioma treatment. However, there are some drawbacks to γ-
secretase inhibitor treatment, including side effects due to Notch and γ-secretase’s activity 
throughout the body.  
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II. Somitogenesis and the segmentation clock 
Somitogenesis is the developmental process that allows somites, which eventually 
develop into vertebrae, ribs, and skeletal musculature, to bud off of the presomitic mesoderm 
(PSM) in vertebrates, located at the distal end of the embryo. This highly regulated process is 
very methodical, occurring every 2 hours in mice, and continues even when the PSM is removed 
from the rest of the embryo and left in culture (Christ et al., 1974). It has been suggested that a 
molecular clock, or the cyclical expression of regulatory genes, provides the necessary temporal 
coordination.  
The current understanding of segmentation is the clock and wavefront model. This model 
suggests that a cell oscillates between permissive and non-permissive states (“the clock”), and 
cells that are close to one another will go through the same state at the same time, thus creating a 
wave of gene expression that passes through the PSM. The period of this oscillation is the same 
as the time between the formation of new somites. As the clock continues, the wavefront moves 
down the PSM caudally, and when cells in the permissive state pass this wavefront, they begin to 
bud off into somites as organized cohorts of cells (Cooke and Zeeman, 1976). Molecular 
evidence for this model was provided when the gene c-hairy1 was shown to cause segmentation 
in a manner that was predicted by the clock model (Palmeirim et al., 1997). 
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Figure 2. The clock and wavefront model showing the posterior undetermined region of the PSM, 
with the anterior region forming pre-somites and somites. The Notch and Wnt pathways are 
responsible for the oscillating clock, where gene expression changes at a timed rate. As the 
wavefront, created by the FGF pathway, meets cells in a permissive state, they start to segment off 
into presomites.  
 
The Notch pathway is critical for controlling the clock. Activation of the Notch pathway 
initiates expression of Hes7, which has been shown to be one of the most important genes for 
segmentation; knocking out or constantly expressing Hes7 causes severely fused vertebrae and 
ribs (Bessho et al., 2001, and Hirata et al., 2004). It is the oscillation of Hes7, as part of the 
clock, that allows for normal segmentation. There are multiple ways that Hes7 expression 
oscillates; first, Hes7 forms a negative feedback loop, and represses its own expression by 
binding to its promoter (Bessho et al., 2001). Cyclical activation of Notch also affects Hes7 
expression, and this is achieved by changing expression of its activating modulators, especially 
Lunatic Fringe. 
Lunatic Fringe (or LFNG) is a glycosyltransferase, that glycosylates the Notch receptor to 
modulate its affinity to bind to other ligands and become activated (Bruckner et al., 2000). LFNG 
activity also fluctuates in the PSM, and constant expression or loss of expression of Lfng causes 
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somite fusion (Evrard et al., 1998). It has been shown that Hes7 negatively regulates LFNG as 
well as itself; when Hes7 is repressed, Lfng is expressed ubiquitously, whereas when degradation 
of Hes7 is inhibited, Lfng is repressed (Bessho et al., 2001). However, it has been found that in 
the PSM, repression of Lfng causes an increase of Notch activity, suggesting that in this context, 
LFNG modulation inhibits the pathway (Shifley et al., 2008). 
III. Glioma  
Glioma is the cancer of the glial cells in the central nervous system, and is the most common 
primary brain malignancy. The most aggressive form, glioblastoma multiforme (GBM), has a 
predicted survival of 12 months with tumor resection, chemotherapy, and radiation (Kanu et al., 
2009). This unfortunate prognosis is largely due to their unique phenotype: GBMs are extremely 
heterogeneous, highly invasive and unusually resistant to chemotherapeutic drugs, and there is 
insufficient understanding of these mechanisms (Wen and Kesari, 2008). The current standard of 
care for glioma, temozolomide (TMZ), is an alkylating agent that causes double-stranded breaks 
in DNA. However, 40% of patients undergoing chemotherapy do not show any response to TMZ 
therapy (Mrugala, 2008); this is partly due to the fact that the cell has a natural way to combat 
this alkylation, using the DNA repair enzyme O6-methylguanine-DNA methyltransferase 
(MGMT). This protein removes alkyl groups, inhibiting the effect of TMZ. It has been shown 
that methylation (and thus inactivation) of the MGMT promoter in tumor cells is correlated with 
better response to TMZ and better survival, with these patients living an average of 9 more 
months than those patients with unmethylated MGMT promoters (Hegi et al., 2005). TMZ has 
also been found to cause secondary cancers, specifically leukemia and skin cancers (Sanderson 
and Shield, 1996), but few other therapeutic options have been successful. 
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Glioma stem cells (GSCs) have been suggested as a source of the glioma tumor and 
contributors to its characteristic invasive nature and high recurrence rate (Wen and Kesari 2008). 
They are thought to be related to “neural stem cells,” progenitor cells in the nervous system that 
are multipotent and are capable of self-renewal, and are responsible for neurogenesis and 
gliogenesis in the fetal brain. GSCs are most commonly identified by expression of CD133, a 
cell surface protein that is characteristic of neural stem cells, however it has been noted that 
probably not all CD133+ cells in a tumor are GSCs (Beier et al., 2008). GSCs are capable of 
multipotency, telomerase activity, self-renewing capabilities, and resistance to apoptosis (as 
reviewed by Dell’Albani, 2008). 
Higher-grade gliomas are often more undifferentiated, suggesting that an increased number 
of GSCs worsen outcome (Phillips et al., 2006). GSCs have been found to grow in neurospheres 
in culture, or small, floating spheres of cells all derived from the same original cell. The outside 
layers of these spheres are heterogeneous, expressing both neuronal and glial markers, but the 
inner core of cells express stem cell markers (Vik-Mo et al., 2011), illustrating GSC cells’ ability 
to create a diverse tumor, one of the major treatment challenges in glioma. CD133 expression 
increases dramatically in recurring gliomas as opposed to their primary tumor (Liu et al., 2006), 
suggesting that GSCs are associated with tumor recurrence and chemoresistance. 
GSCs are relatively quiescent, and their slow replication means that they are not as affected 
by alkylating drugs as other tumor cells, allowing them to survive with no or relatively few DNA 
breaks until treatment is over. CD133+ cells also have higher expression of the MGMT protein 
than CD133- cells in the same tumor, meaning they are able to avoid the effects of TMZ (Liu et 
al., 2006); this could be partially responsible for the glioma’s lack of response to treatment. All 
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of this implies that GSCs may be one of the major problems in glioma, and to treat the disease 
we need to target these initiating cells.  
The Notch pathway is upregulated in undifferentiated embryonic CNS cells, and is 
hypothesized to inhibit differentiation (Lasky and Wu, 2005); because of this, it has become of 
new interest in glioma. Notch activation in glioma cells has been shown to enhance DNA repair 
through the Akt pathway, promote cell growth and tumor formation (reviewed in Natsume et al., 
2011), and its upregulation is considered a hallmark of GSCs. Notch expression has been shown 
to induce a GSC phenotype: when the NICD fragment of the Notch receptor was stably 
transfected into a glioma line, it was found to have higher colony- and sphere-forming 
capabilities, both markers of GSCs (Zhang et al., 2008). But inhibition of Notch-1 has proven 
deadly to GSCs. When Notch activity was inhibited by γ-secretase inhibitors, the CD133+ 
population was decreased 5-fold. While more differentiated cells’ growth was unaffected by 
Notch activity inhibition, their ability to form colonies and tumor xenografts was suppressed, 
suggesting that the cells that initiate and propagate the glioma were gone (Fan et al., 2006). 
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Figure 3. The role of the Notch pathway in glioma stem cell creation. Normally, Notch maintains 
normal neural stem cells and pushes progenitor cells towards a glial cell fate. However, Notch can 
also cause de-differentiation in the cell; this causes the cell to become self-renewing, increase 
DNA repair ability, and become quiescent. While Notch is not the only mechanism involved in 
GSC creation (for example, other pathways must be mutated to change regulation of cell 
replication), it is the beginning of a series of pathogenic mutations leading to cancer stem cells 
(adapted from Goldthwaite, 2006). 
 
Drug targets for GSCs are essential if the prognosis of GBM is to be improved and the 
recurrence of glioma is to be reduced. If GSCs are responsible for glioma recurrence and are 
unresponsive to TMZ, then we are not treating the source of the problem. As the current standard 
of care, TMZ only prolongs the disease without eradicating the tumor source, but unfortunately, 
it is currently the best treatment we have. GSCs’ quiescent nature makes current therapies less 
effective, as many cancer treatments require the cells to be actively replicating. Most targets of 
current interest would cause the GSCs to differentiate and begin to replicate more quickly, 
making them susceptible to conventional treatment. These targets include the Notch, Wnt, and 
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Hedgehog pathways, which are all required for stem cell growth. By utilizing our knowledge of 
normal neural stem cells and cell differentiation in the brain, we can begin to target GSCs. 
IV. DLL-3 
The most structurally divergent Notch ligand is DLL3; it is considered to have a degenerate 
DSL domain, the segment that interacts with the Notch receptor and is a commonality between 
all other Notch ligands. It also lacks the DOS (Delta and OSM-11) motif and intracellular lysine 
residues, which are both considered central to trans-activation (as reviewed in D’Souza, 2010).  
DLL3 has been shown to lack the ability to trans-activate Notch-1 in normal development, but 
when expressed in the same cell as Notch it can cis-inhibit (Geffers et al., 2007; Ladi et al., 
2005). DLL3 has been shown incapable of replacing DLL1, a ligand that can both activate and 
inhibit the Notch pathway, (Geffers et al., 2007) 
It has been proposed that DLL3 targets Notch-1 for lysosomal degradation, therefore 
preventing cell membrane presentation and sequestering the ligand in the Golgi (Geffers et al., 
2007), although other authors have found that DLL3 bound to Notch-1 does not prevent its 
exposure in the membrane (Ladi et al., 2005). In addition to these conflicting explanations, the 
subcellular expression of Dll3 has never been analyzed in tumor cells, underscoring the need to 
further understand the molecular mechanisms of this protein in cancer. 
Importantly, Dll3 expression was found to be higher in proneural GBM samples that had 
better prognoses. These tumors did not have upregulated Notch-1, suggesting that its Notch-
inhibiting properties could naturally decrease malignancy (Phillips et al., 2006). Fibulin-3 is a 
protein normally not present in the brain, but has been found to be upregulated in gliomas. It has 
been shown to be an activator of Notch signaling, and promotes invasion and tumor survival. 
Downregulation of Fibulin-3 caused apopotosis, and impaired the growth of intracranially-
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implanted tumors. DLL3 has been shown to antagonize and coprecipitate with Fibulin-3, 
effectively inhibiting its activation of the Notch signaling pathway (Hu et al., 2012). However, 
DLL3 has never been purposefully manipulated to study its effects on Notch-1 activity and 
resulting tumor phenotype.  
          
Figure 4. Kaplan-Meier survival plot of gliomas with different Dll3 expression levels. 
Downregulated Dll3 (2x below the average Dll3 expression) has a worse outcome than all glioma 
tumors (p-value= 0.002), while upregulated Dll3 (2x above the average expression) has a better 
prognosis (p-value<0.001). This suggests that DLL3 is involved in promoting a more treatable 
tumor, possibly through the Notch pathway. Data from REMBRANDT (National Cancer 
Institute). 
 
DLL3 usually inhibits Notch activity, which would explain why increased expression of Dll3 
prolongs survival. However, Notch modulation is very context dependent; loss of Dll3 in the 
PSM decreases Notch activity suggesting that in that context, DLL3 is involved in Notch 
activation. Thus, our objectives focused on starting to understand the function of DLL3 in a 
context where it activates Notch and examine the role of DLL3 in the Notch pathway in glioma 
cells. By understanding the role DLL3 plays in two different contexts, we can begin to 
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understand if DLL3 could present a unique opportunity as an endogenous inhibitor of Notch 
signaling that could be used to develop targeted therapies against glioma. 
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Objectives 
Specific Aim 1: What is the epistatic relationship between Lunatic Fringe and DLL3? 
Based on previous phenotypic findings in mice, we hypothesize that DLL3 will be 
epistatic to LFNG. By understanding the relationship between these two modulators, we 
can understand the function of DLL3 in normal development, its ability to control the 
Notch pathway, and its potential as a glioma treatment target. 
Specific Aim 2: What are the effects of overexpressing Dll3 in glioma cells? 
We hypothesize that Dll3 overexpression will decrease Notch activity and will affect 
Notch-dependent phenotypes, like chemoresistance, but will not change Notch-
independent phenotypes, like viability, because of DLL3’s specificity to the Notch 
pathway. 
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Materials and Methods 
Mice strains and upkeep 
 Lunatic Fringe null (LfngtmRj01) and DLL3 pudgy (DLL3pu) mice have previously been 
described (Evrard et al., 1998; and Kusumi et al., 1998). Mice were maintained on mixed 
1295v/C57BL6/GVB backgrounds by intercrosses of DLL3pu/+; Lfng+/- mice. For timed 
pregnancies, cages were checked daily with noon of the day of plug detection defined as 0.5 
d.p.c. (days post coitum). All procedures were conducted under protocols approved by the OSU 
IACUC. 
Mice and embryo genotyping was completed using tail preps and yolk sacs, respectively. 
For tail DNA analysis, samples were processed overnight with ProteinaseK, then DNA was 
salted out using sodium chloride and washed with ethanol. Yolk sac DNA was prepared via the 
HotSHOT procedure (Truett et al., 2000). PCR genotyping used primers SC355 (5’-
GCCTCTTCTTCAGGGTCTGC-3’) and SC356 (5’-ACTCACCGGCCAAGCATC-3’) for Dll3; 
and FNG322 (5’-GAGCACCAGGAGACAAGCC-3’), FNG325 (5’-
AGAGTTCCTGAAGCGAGAG-3’), and PGK3 (5’-CTTGTGTAGCGCCAAGTGC-3’) for 
Lfng. The Dll3 PCR products were digested with HaeIII (from Biolabs) for 2 hours at 37° C. 
PCR/digest products were run on a 2.5% agarose gel and analyzed by comparison to controls. 
Lfng PCR produced bands at 410 bp (Lfng-/-), 380 bp (Lfng +/+), or both (Lfng +/-). Dll3PCR and 
digest produced bands at 1000 bp (Dll3+/+), 1300 bp (Dll3p/p), or both (Dll3+/p). 
Whole mount immunohistochemistry 
10.5 d.p.c. mouse embryos were dissected and fixed in 4% PFA overnight. Embryos were 
washed in methanol and bleached overnight. After washing in PBS and CT, embryos were 
heated and incubated in primary antibody against NICD (Cell Signaling) at 1:300 dilution for 5 
 19 
days at 4° C. Embryos were washed in MABT and incubated overnight with AP-tagged anti-
rabbit IgG secondary antibody (Cell Signaling cat. #4147) at a 1:500 dilution. After exposure to 
the antibodies, embryos were washed with MABT+2 mM Levamisole overnight. Detection was 
performed in detection solution, and the embryos were checked every 30 minutes until desired 
staining appeared. Embryos were washed, dehydrated with methanol, and rehydrated. Embryos 
were then cleared in 1:1 Glycerol:PBT and 4:1 Glycerol:PBT. 
Skeletal Preparations 
17.5 d.p.c. mouse fetuses were skinned and fixed in 95% ethanol for five days. The fat 
was removed by placing the fetuses in acetone for 2 days. They were stained for 3 days at 37° C 
in 0.015% alcian blue and 0.005% alizarin red. After staining, the fetuses were washed with 
distilled water and cleared in 1% KOH in 20% glycerol as needed, with progress being 
monitored every 3-4 days. They were then moved into 50%, 80%, and 100% glycerol for 
storage. 
Cell culture and expression constructs 
The major cell line to be used for this project was the rat glioblastoma cell line CNS-1. 
These cells share many properties of invasive human glioma with neural progenitor-like 
characteristics, including nuclear atypia, pleomorphism, and expression of glial and neuronal 
proteins, including Notch (Kruse et al., 1994). Cell lines were obtained from Mariano Viapiano. 
RPMI media with 10% FBS was used for culture, with media being changed every 4 days; cells 
were passed using 0.05% Trypsin as needed. 
Overexpression of Dll3 was achieved by transient transfection with JetPrime transfection 
reagent with a full-length rat Dll3 clone carried in the vector pcDNA4.1/V5x6His. 
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Quantitative RT-PCR 
To observe endogenous Dll3 transcription, qRT-PCR was performed. RNA was isolated 
from CNS-1 cells or rat brain, and underwent reverse transcription into cDNA (Superscript RT, 
Invitrogen). Quantitative PCR with the obtained cDNA using SYBR Green was then performed 
with primers for Dll3 (5’-TTTCCAAGGCTCTAACTGTG-3’ and 5’-
AGGTCGTGCTCGCAGCGT-3’) and GAPDH (5’-AGTCCATGCCATCACTGCCAC-3’ and 
5’-ATGACCTTGCCCACAGCCTTG-3’). GAPDH is an enzyme involved in glycolysis and is 
expressed in every cell; it is therefore used to determine the amount of cDNA present. Dll3 
expression was normalized using GAPDH. 
Luciferase co-culture assays 
 Cells were counted and plated (40,000 CNS-1 cells per well in 24-well plate and 200,000 
per well in 6-well plate). After 24 hours, the cells in the 24-well plate were transiently 
transfected with 100 ng of JH-26 (CBF-controlled Luciferase), 100 ng pBOS-Notch1, 10 ng 
renilla (transfection control), and 500 ng of an interest gene (either pcDNA control or Dll3). 
Cells in the 6-well plate were transiently transfected with either 2 µg of pBOS or Dll1 expression 
vector. After 24 hours, 15,000 cells from either the pBOS or Dll1 wells were placed in each of 
the 24-well plates. After 24 hours, cells were lysed with Passive Lysis Buffer and luciferase and 
renilla levels were measured with a luminometer and a Promega Luciferase Kit. To control for 
varying transfection efficiencies, luciferase activity was normalized to renilla activity (L/R). 
Experiments were performed in triplicate. 
MTS viability assays 
 Cells were transfected with either a pcDNA control vector or Dll3, then counted and 
plated (5,000 CNS-1 cells per well in a 96-well plate). Cells were left to grow for 2-7 days. At 
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different time points, MTS reagent (from the Promega CellTiter kit) was added and the plate was 
incubated until sufficient coloration had appeared. MTS is reduced in metabolically active cells 
into formazan. The absorbance of formazan at 490nm can be measured, and is directly 
proportional to the number of active cells. Numerical data was derived from a plate reader, 
which measured absorbance at a wavelength of 490 nm. Experiments were performed in 
triplicate. 
Analysis of chemoresistance 
To examine the effect of DLL3 on cells’ resistance to chemotherapy, cells were 
transfected with the pcDNA-Dll3 construct or an inert control plasmid, and 24 hours later 
exposed to 400 micromolar temozolomide (TMZ), the standard of care chemotherapeutic drug 
for glioma, or isovolumetric DMSO for varying time points. Cells were assessed by MTS redox 
assays to determine if changes in DLL3 activity affected the cells’ ability to survive treatment. 
Statistical Analysis 
Grouped results were analyzed by t-tests or one/two-way ANOVA according to the experimental 
design. All differences were deemed significant at p<0.05. 
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Results Pertaining to Segmentation 
The first objective of this thesis was to study the interaction between the Notch 
modulators DLL3 and Lunatic Fringe. We hypothesized that Dll3 would be epistatic to Lfng 
because of previous results based on phenotype, however the relationship between the two 
modulators has not been studied on a molecular basis. 
To achieve this, we used a cross of mice that have Lfng knocked out (Evrard et al., 1998) 
and those with a dysfunctional Dll3 allele, called pudgy (Kusumi et al., 1998). By using mice 
that have nonfunctional Lfng and Dll3, we were able to see which gene controlled the phenotype 
of the mice that were homozygous for both mutations (also known as “double mutants”).  
 
Figure 5. Lfng PCR genotyping results (Image A) show homozygote wildtype embryos (lanes 1, 7, 
and 15), heterozygotes (lanes 2-6, 8, 10-14, 16), and homozygote null embryos (lane 9); these 
were compared to a Lfng null control in lane 17. Dll3 genotyping (Image B) show homozygote 
wildtype (lanes 1, 10, 12), heterozygotes (lanes 2-8, 11), and homozygote pudgy (lane 9); these 
were compared to a heterozygote (lane 13) and homozygote pudgy (lane 14) control. 
Heterozygotes of both Lfng and DLL-3 were classified as wildtype, as both mutations are loss-of-
function.  
 
Double mutant embryos show DLL-3 mutant Notch activation pattern 
 To observe how Notch activation changes in double mutants, 10.5 d.p.c. mouse embryos 
were probed for NICD, the activated form of Notch-1, in the presomitic mesoderm (PSM) by 
whole mount immunohistochemistry using an antibody that is specific for the cleaved NICD 
fragment. Instead of studying the basic expression of Notch, this shows where the pathway has 
been activated, and where expression of target genes would be expected. The modulators 
(including LFNG and DLL3) do not control the concentration of the Notch receptor, only the 
activation of it, so this allows us to study their role in affecting the Notch pathway. 
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Figure 6. Wildtype (a-c, n=6), Lfng-null (d, n=4) Dll3-pudgy (e, n=5), and double-mutant (f, n=4) 
presomitic mesoderms of 10.5 d.p.c. mouse embryos. The embryos with both Lfng and Dll3 
knocked out have a similar Notch activation pattern to those of Dll3-pudgy embryos in the 
posterior PSM, in that both show decreased Notch activation in comparison with the wildtype and 
Lfng-null embryos. However, in the anterior PSM the double mutants’ phenotype appears more 
severely affected than the Dll3-pudgy embryos, as their Notch activation bands are fainter. 
 
In the wildtype embryos, the bands of activation oscillate, as expected; since each 
embryo is caught in a different stage of the cycle, we observe several distinct patterns of 
activation. In embryos with Lfng knocked out, Notch activity is visible throughout the whole 
PSM, running counter to what we know of the LFNG/Notch relationship. When an activator of 
Notch (like LFNG) is knocked out we would expect a decrease in activity; thus it seems that in 
the PSM, LFNG is involved in Notch pathway inhibition. When Dll3, which is usually 
considered an inhibitor of Notch, is knocked down, Notch activity decreases when we expected 
increased activity of Notch. This suggests that the associations between Notch and its modulators 
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are much more complex than we currently understand. As such, it is important that more 
research is done to establish the complex associations in this pathway. 
In embryos with both Lfng and Dll3 knocked out, the embryos show a similar expression 
pattern to Dll3 knockouts in the posterior PSM, however they are more severely affected in the 
anterior PSM (which is not regulated by the clock) as the bands appear fainter. In the clock, 
which controls the posterior PSM, the Dll3 phenotype is epistatic to Lfng, suggesting that LFNG 
acts on Notch in a way that requires DLL3 activity. In the anterior PSM, which is clock-
independent, the phenotypes seem additive, suggesting that Lfng and Dll3 act in parallel 
pathways. 
Double mutant mouse skeletons show worse phenotypes 
 The regular action of both DLL3 and LFNG as modulators of the Notch pathway is 
crucial to normal skeletal development, however the two have rarely been studied together. To 
study the effect of both mutations on axial skeletal phenotype, 17.5 d.p.c. mouse fetus skeletons 
were selectively stained for bone and cartilage using alizarin red and alcian blue, respectively. 
Regulation of Notch signaling is imperative for normal axial skeleton development; by studying 
mice with both mutations, we will be able to assess which gene is epistatic to the other and 
controls the ultimate phenotype of the mouse.  
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Figure 7. Skeletal preparations of 17.5 d.p.c. mouse fetuses of indicated genotypes were 
performed using alizarin red to stain bone and alcian blue to stain cartilage. Views of the ribs, both 
dorsal (a-d) and ventral (m-p) are shown, as well as a dorsal view of the sacral region (e-h) and a 
coronal view of the sacral region (i-l).  
 
Mutations in either Lfng or Dll3 alone causes disorganization in the ribs and 
spine, including offsetting of the ventral ribs’ pairings, bifurcations and unattachments of 
the dorsal ribs, and unorganized patterning of the vertebrae. There is more visible rib 
disorganization in the double mutants’ ribs than either the Lfng-nulls or the Dll3-pudgy 
skeletons, as seen in the dorsal view of the ribs, however from the ventral view the ribs’ 
cartilage does not appear more affected. There is no rescuing of the double mutants’ 
phenotype in the posterior vertebrae, as there is in Lfng-nulls, suggesting that in the 
posterior, Dll3 is epistatic to Lfng. We also observed that double mutants lack organized 
neural arches (as visible in the coronal view of the sacral region), which are present in 
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both Lfng-nulls and Dll3-pudgy mice. This suggests that the formation of neural arches is 
dependent on the presence of one of these genes, and that a nonfunctional Lfng or Dll3 
can be rescued in the neural arches by the action of the other. 
These results indicate that there are different relationships between DLL3 and LFNG in 
the anterior and posterior PSM, which then manifest themselves in the skeletal phenotype. There 
is no clear epistatic relationship between Dll3 and Lfng in the anterior PSM. It appears that 
DLL3 and LFNG act together in the controlling of the Notch pathway through parallel systems, 
which causes a decrease in Notch activation in 10.5 d.p.c. double mutant embryos’ anterior 
PSMs, and a worsening of rib abnormalities in 17.5 d.p.c. skeletons. We also found that the two 
genes interact in previously undescribed ways to form neural arches, suggesting that one of these 
two parallel systems is required for the development of neural arches. In the posterior PSM, Dll3 
is epistatic to Lfng, which prevents the clock from organizing the developing somites.  We may 
speculate that this is why in the posterior vertebrae, there is no rescuing of the double mutants’ 
phenotype as there is in Lfng-null mice. While we see that in the context of the clock, DLL3 is 
required for LFNG activity, in a clock-independent situation they function collaboratively. This 
data shows us that even in the single process of segmentation, the effects of DLL3 and other 
modulators, like LFNG, can have distinct effects on Notch signaling in different contexts. This 
makes it critically important to understand exactly how Notch is being regulated in gliomas 
before we begin to target it in therapy. 
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Results Pertaining to Glioma 
 The second aim of this project was to study the effect of overexpressing Dll3 in glioma 
cells. As previously shown, upregulated Dll3 betters survival of glioma, however its role is not 
clear. We hypothesized that an overexpression of Dll3 would decrease Notch activity, and tested 
this by Luciferase assay. We also wanted to observe whether the overexpression of Dll3 would 
cause phenotypic changes, so both Notch-independent (cell viability) and Notch–dependent 
(chemoresistance) phenotypes were tested.  
DLL3 is underexpressed in CNS-1 cells compared to normal rat brain tissue 
 In the interest of familiarizing ourselves with the relative expression of Dll3 in our main 
cell line, gel electrophoresis and quantitative RT-PCR were performed on normal rat brain and 
CNS-1 cells.  
 We find that CNS-1 cells have extremely low DLL3 expression compared to both rat 
brain and rat embryo. Qualitatively, Western blot analysis showed that rat brain and rat embryo 
have more DLL3 protein than CNS-1 cells. By performing qRT-PCR with a GAPDH control, we 
found that when normal Dll3 expression in rat brain RNA is normalized to 1.0, the expression of 
Dll3 in CNS1 cells is only 0.003 fold of that in brain, showing that glioma cells have 
significantly lower endogenous Dll3 expression than normal tissue. 
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 Figure 8. Endogenous DLL3 expression in the rat glioma cell line, CNS-1, was measured by both 
Western blot and qRT-PCR. When normalized to normal rat RNA, CNS1 Dll3 mRNA levels are 
only 0.003 fold. In both cases, the DLL3 expression in the glioma cells was much lower than in 
normal rat brain, suggesting that this may contribute to why NICD is so highly expressed in CNS-
1 cells. 
 
 CNS-1 cells are known to have high NICD activity (Kruse et al., 1994), so the 
results fit with the hypothesis that low Dll3 expression means higher Notch activity and 
vice versa. Low expression of Dll3, a Notch inhibitor, in glioma cells could facilitate for 
overactive Notch pathway activity, contributing to the glioma stem cell phenotype. This 
finding also led to the conclusion that it would not be useful to complete experiments 
with Dll3 siRNA in glioma cells as originally planned. As the endogenous Dll3 in CNS-1 
cells is so low, it is likely that no effect would be observed by knocking down Dll3, and 
thus only experiments where Dll3 was overexpressed were conducted. 
Overexpression of Dll3 causes a decrease in CBF-1-controlled gene expression 
 To study the effect of DLL3 on Notch-1 activation, we performed Luciferase co-culture 
assays. Using a promoter that is activated by the CBF-1 transcription factor and a luciferase 
reporter gene, luciferase expression can be quantified and thus the activity of the promoter can be 
measured. CBF-1 is known to be activated by NICD, so as activation of Notch increases, the 
expression of luciferase will increase. Cells expressing both the reporter gene, renilla 
(transfection-efficiency control), and either pcDNA3 (control vector) or Dll3 were co-cultured 
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with cells transfected with pBOS (control vector) or Dll1 (an activator of the Notch receptor). 
The role of the Dll1 cells was to deduce whether DLL3 could not only reduce the endogenous 
activity of Notch, but continue to repress Notch activity in the presence of a Notch activator. 
When co-cultured with pBOS control cells, DLL3 lowered luciferase activity, and thus 
Notch-dependent CBF-1 activity (p<0.001*). This decrease remained even in the presence of 
DLL1 (p=0.0056*), suggesting that DLL3 is a potent inhibitor of Notch activity even when in 
the presence of overexpressed Notch activators. 
 
Figure 9. pcDNA or Dll3 were transiently transfected into CNS-1 cells (stably transfected with a CBF-1 
controlled lucierase gene) along with a renilla control by Lipofectamine transient transfection. The 
Luciferase/Renilla values were used for data analysis. DLL3 decreased promoter activity when co-cultured 
with a pBOS control (p<0.001*) and the Notch-activator DLL1 (p=0.0056*). 
 
This data show us that DLL3 decreases Notch-dependent transcription, most likely by 
decreasing Notch-ligand interactions, which decrease Notch activation and transcription of 
Notch target genes. This suggests that other Notch targets under CBF-1 control, which are 
responsible for the glioma stem cell phenotype, would also be downregulated by exogenous 
Dll3, supporting the potential use of DLL3 as a glioma treatment.  
 
 30 
Overexpression of Dll3 does not change cell viability or proliferation 
We proposed that cell viability will not be affected by Dll3 expression, as the knockdown 
of Notch-1 has not been found to cause cell death or a change in metabolic activity. Cell viability 
was measured in an MTS assay, comparing CNS-1 cells transiently transfected with P16 (control 
vector) or Dll3. There is no statistical difference between the two groups (p-value for Day 7= 
0.4750). This supports the hypothesis that a change in Dll3 expression does not affect Notch-
independent phenotypes; viability is not a phenotypic effect of the pathway and so remains 
unchanged. However, cells continue to proliferate throughout the assay, as the MTS absorbance 
increases; proliferation is Notch-dependent, thus we would expect to see Dll3-expressing cells 
stay at a relatively constant MTS absorbance as the cells don’t proliferate but don’t die either, 
while the control cells continue to grow. 
 
 
Figure 10. A MTS assay was performed to measure cell viability. CNS-1 cells were transiently 
transfected with Dll3 or pcDNA, plated at 5,000 cells/well, then left to grow for 2-7 days. At 
different time points, the MTS reagant was added and absorbance at 490 nm was measured. No 
statistical significance was found (p-value for Day 7 =0.4750), which suggests there is no change 
in viability. However, we would expect proliferation to decrease in the Dll3-expressing cells, as it 
is Notch-dependent, however the proliferation remains equal between the two cell populations. 
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 We had many issues with overexpressing and detecting Dll3 in CNS-1 cells, so this may 
be due to insufficient Dll3 expression, meaning we cannot extrapolate the viability data either. If 
we could more robustly express Dll3, we would expect to see decreased proliferation. To 
differentiate between viability and proliferation, we will need different assays as well, for 
example one that measures cell death, where we would expect to see no difference between the 
control and Dll3 cells. We could also use flow cytometry to see how many cells are actively 
replicating, where we would expect to see fewer cells transfected with Dll3 replicating. 
It is important that viability is unchanged when Dll3 is overexpressed because this 
suggests that DLL3 could be targeted as a treatment for glioma without affecting other cell 
functions. Unlike current chemotherapy treatments like TMZ, a DLL3 treatment may not kill 
other cells, which results in adverse effects. However, a distinction to be made in this experiment 
is that the MTS viability assay does not measure cellular life, but metabolic activity. The assay 
does not differentiate between quiescent cells and dead cells. This experiment does not tell us if 
cells are coming out of quiescence at all, or if cells are dying, only that the relative amount of 
metabolic activity is the same. In the future, it will be important to decipher whether DLL3 can 
affect cell quiescence, as this is a hallmark of glioma stem cells and one of the major difficulties 
with current treatments. 
Dll3 was not shown to affect chemoresistance 
 The Notch pathway has been suggested as a possible source of chemoresistance in 
glioma, and upregulation of Notch-1 in glioma causes cells to become more resistant to the 
standard of care chemotherapy, TMZ (Purow et al., 2005). For this reason, we proposed that 
upregulation of Dll3 would cause a decrease in chemoresistance of glioma cells. Cells were 
transfected with a P16 pcDNA control or Dll3, then exposed to either isovolumetric DMSO or 
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TMZ (final concentration of 400 µM). At various time points after exposure (Days 2, 4, and 6), 
cell viability was measured by MTS assay. There was no significant difference (p-value for Day 
6= 0.2624) between P16 and DLL3 cells, suggesting Dll3 expression does not change 
chemoresistance. However, there was no statistical difference between cells treated with DMSO 
and TMZ, meaning that treatment with TMZ did not work and wasn’t killing cells. 
 
 
Figure 11. CNS-1 cells were transiently transfected with Dll3 or P16 control, plated at 5,000 
cells/well, then exposed to 400 micromolar TMZ or isovolumetric DMSO 24 hours later. Cells 
were left to grow for 2-6 days. At different time points, a MTS assay was performed and 
absorbance at 490 nm was measured. No statistically significant difference was found between 
P16 and Dll3-expressing cells (p-value for Day 6= 0.2624). However, cells in TMZ appear to have 
similar survival to cells in the DMSO control, suggesting that our TMZ treatment did not work. 
 
It is very important to determine whether Dll3 expression affects chemoresistance, as this 
is one of the major issues with current glioma treatment that we are hoping to address. While 
these results are not supportive of our hypothesis, we will need to optimize our TMZ treatments 
before we can draw conclusions about the role of DLL3 in chemoresistance. It is possible that 
our CNS-1 cell line acquired resistance to TMZ, or that the treatment protocol was not being 
followed correctly. Until our results can show statistically significant drug treatment similar to 
other published results, we cannot determine whether Dll3 overexpression affects 
chemoresistance.  
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Discussion 
The Notch pathway has a complex mechanism of action  
 Through our studies on double mutants’ axial skeletal development, we found that when 
both Dll3 and Lfng are knocked out, the phenotype is worse than a mutation in just one of the 
genes. We previously believed that the double mutants would resemble Dll3 pudgy mutants, but 
it is now clear that LFNG and DLL3 act differently throughout the PSM to influence 
development. This shows that the Notch pathway is not a linear pathway throughout the entire 
PSM; if it were, the inhibition of DLL3 activity would result in the same phenotype as the double 
mutants. Instead, we found that in the posterior PSM, where the clock is active, Dll3 is epistatic 
to Lfng, while in the anterior PSM, they act together in parallel pathways. Very little research has 
been done on these two modulators together, and investigation of the Notch pathway is 
complicated by the numerous ligands that activate/inhibit the receptor. 
In our immunohistochemistry experiments, we found that Lfng-null embryos have 
activated Notch throughout the PSM, and inhibition of Dll3 causes a decrease in Notch activity. 
This runs counter to the canonical knowledge of LFNG as an activator of Notch and DLL3 as an 
inhibitor. When an activator is knocked out, activity is expected to decrease, and vice versa for 
an inhibitor. Why this occurs is not clear, but it appears that our understanding of Notch and the 
role it plays in different contexts is not complete. 
We also found that while mice with either Dll3-pudgy or Lfng-null mutations have 
formed neural arches (the posterior part of the vertebra), double mutants do not. This implies that 
there is a rescue-of-function in single mutation mice, and that neural arch development can occur 
with either Lfng or Dll3 present. This is surprising, as the two have very different functions, 
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LFNG as a Notch activator, and DLL3 as an inhibitor. Why the other ligands that are present in 
the pathway cannot rescue the development of neural arches in double mutants is also not clear.  
The Dll3 phenotype is epistatic to the Lfng phenotype in the segmentation clock 
Through our use of immunohistochemistry, we found that 10.5 d.p.c. mouse embryos 
with both Lfng and Dll3 mutations have a similar Notch activation pattern to Dll3 pudgy 
embryos in the posterior PSM, where the clock is active. This suggests that Dll3 is epistatic to 
Lfng, meaning that LFNG activity depends on the presence of DLL3 or that DLL3 activity 
occurs first in the pathway. This also shows that the two modulators interact with the Notch 
receptor through a similar mechanism, which is why the double mutants resemble the pudgy 
mutants instead of a mixture of the two single mutants. By showing that DLL3 activity can 
influence LFNG activity, we can utilize DLL3 in both CNS development and glioma when 
trying to downregulate Notch, because LFNG will not be able to negate DLL3’s effects.  
However, this relationship is not epistatic in the anterior PSM, where somites are 
patterned and the clock is no longer active. The bands of activation in double mutants were more 
faint than in the Dll3-pudgy mutants. Why this occurred, as opposed to an upregulation in the 
posterior PSM like the Lfng mutants, is not clear. While these results show us that Dll3 is 
sometimes epistatic to Lfng, to fully understand the DLL3/LFNG relationship, we will need to do 
further experiments to explain the mechanism behind this relationship. 
The Notch pathway is an important glioma treatment target 
 Through both Western blotting and qRT-PCR, we saw that DLL3 expression is much 
lower in the rat glioma cell line, CNS-1, than in normal rat brain. This, along with the fact that 
CNS-1 cells have been shown to have high NICD expression (Kruse et al., 1994), suggests that 
low DLL3 expression means high Notch activity. Thus, by upregulating Dll3, we hypothesized 
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we could decrease Notch activity. These results also led us to the decision to not attempt 
knocking down Dll3 in CNS-1 cells as a comparison to upregulation, as the effects of 
knockdown would be very small. 
 The recent clinical success of γ-secretase inhibitors in glioma also suggests that inhibition 
of Notch activity can better patient outcomes. However, there are some drawbacks to γ-secretase 
inhibitor treatment. Notch signaling is active throughout the body, so inhibiting the pathway 
could have many side effects. For example, because Notch signaling is critical for normal 
intestinal differentiation, γ-secretase inhibitors cause progenitor cells to differentiate into goblet 
cells, interfering with the intestinal epithelium, which is already sensitive due to chemotherapy. 
Besides cleaving the NICD fragment, γ-secretase plays other roles in the body, including the 
cleavage of amyloid precursor protein (APP). The drug does not differentiate between the 
different roles of γ-secretase, and so will interfere in other pathways as well. γ-secretase 
inhibitors can also target similar proteins, like α- and β-secretase, which have a variety of 
functions (reviewed in Shih and Wang, 2007). This makes these drugs’ long-term effects hard to 
predict, and gives reason to pause when considering them as a therapeutic option.  
DLL3 is a promising inhibitor of the Notch pathway in glioma 
 Using Luciferase co-culture assays, we found that overexpression of Dll3 does decrease 
Notch target activity. While this does not actually measure the activity of NICD, it focuses on the 
transcription of target genes, which is the main way that Notch affects phenotype. By showing 
that Dll3 overexpression does not affect Notch-independent phenotypes, like viability, we can be 
hopeful that DLL3 would have fewer side effects than current chemotherapy treatments, like 
TMZ, which targets all replicating cells. Instead, DLL3 treatment could leave normal cells alone 
and allow for patients to have fewer side effects than conventional chemotherapy. While we did 
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not see the expected changes in proliferation, we believe this is because of transfection errors 
that did not allow us to reach the necessary amount of Dll3 expression. 
 Our chemoresistant assays did not generate any helpful data because of issues with the 
TMZ treatment. The TMZ did not kill the cells any more than the DMSO control (which was 
isovolumetric to the DMSO used to solubilize the TMZ). This could be because of a problem 
with the TMZ compound itself, the dosage, or the DMSO; the cells could also have developed 
resistance to TMZ after extended periods of being in culture. We will need to spend more time 
optimizing TMZ treatment and experimenting with other cell lines to determine the source of the 
problem. Nevertheless, these results should not deter further exploration of DLL3 and its role in 
chemoresistance. 
 Another point of interest is that Lunatic Fringe, an activator of the Notch pathway, is 
relatively upregulated in glioma with poorer outcomes. Glioma patients with underexpressed 
Lunatic Fringe have a better survival (p-value= 0.04 when compared to intermediate Lfng 
expression). This suggests that LFNG activation plays a role in Notch’s hyperactivity in glioma 
and contributes to a GSC phenotype that worsens survival. Our epistasis results give hope that by 
upregulating Dll3, we could negate the activating effects of LFNG in glioma. Very little research 
has been done on LFNG in glioma, and by focusing on DLL3’s ability to overpower activators of 
the Notch pathway, like LFNG, we can begin to understand more of the mechanism of this 
complex relationship. 
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Figure 12. Kaplan-Meier survival plot of gliomas with different Lunatic Fringe expression levels. 
Underexpressed Lunatic Fringe (2x below the mean expression) has a better survival outcome than 
both intermediate Lunatic Fringe expression (p-value=0.04) and overexpressed Lunatic Fringe (p-
value=0.05). This suggests that Lunatic Fringe may be involved in glioma development and 
metastasis. However, there is no statistical difference in survival between gliomas with 
intermediate and overexpressed Lunatic Fringe (p-value=0.84). Data from REMBRANDT 
(National Cancer Institute). 
 
Future Directions 
In our studies of segmentation, further research on how DLL3 and LFNG interact should be 
completed. In particular, looking at the effects of the Dll3-pudgy/Lfng-null double mutations on 
Hes7 expression in the PSM would reveal if there are further changes in the downstream 
pathway from mutations in either gene. The use of mouse models that constitutively overexpress 
Dll3 and Lfng could act as a useful supplement to studying how the two ligands interact. 
Moving forward with our glioma research, we should focus on GSC phenotypes, like 
chemoresistance and regeneration of heterogeneous tumors, when Dll3 is overexpressed. This 
would give more evidence as to whether our hypothesis that DLL3 increases survival by 
decreasing GSCs is correct. To do this, we must optimize our chemotherapy treatment, as we 
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struggled with treating CNS-1 cells with TMZ. While the use of TMZ is ideal, as it is the current 
standard of care for glioma, a different glioma cell line might be more susceptible to treatment. 
Another way to study DLL3’s role in GSCs is to use a GSC line, or a cell line where the 
proportion of CD133+ cells is high. While the overall effect of overexpressing Dll3 may be 
small when the percentage of CD133+ cells is low, by studying CD133+ cells only we can study 
DLL3’s specific effects on GSCs. 
Based on the results from future experiments, we may want to pursue the creation of stable 
cell lines with overexpressed/knockdown Dll3. These cells could be implanted intracranially in 
mice to analyze tumor development and progression compared to control glioma cells. Another 
exciting direction of this project would be to explore possible therapeutic strategies targeting 
DLL3. DLL3 itself could be administered intravenously to mice with glioma tumors. If DLL3 is 
not a viable therapeutic option itself, exploration into possible activators of DLL3 would need to 
be started. DLL3 appears to be a promising inhibitor of Notch activity in glioma cells, suggesting 
it could be targeted in future treatment options. If DLL3 can be used as a target for future Notch 
inhibition in glioma, we may be able to make gliomas more susceptible to current treatments and 
improve patient outcomes. 
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